Wegovy, Ozempic, Mounjaro weight loss drugs spawn new products

Novo Nordisk’s Wegovy weight loss drug has seen a meteoric rise in popularity. 

Nurphoto | Getty Images

LONDON — The rapid rise of weight loss drugs like Wegovy and Mounjaro is generating a host of new product lines as companies hope to land on the right side of the health care disruptor.

Industries spanning food and beverage to retail and fitness have come under the spotlight amid surging demand for Novo Nordisk and Eli Lilly’s so-called miracle drugs over concerns that they could dramatically shift consumer habits.

However, some companies say they are embracing the newfound market opportunity.

Dutch Bioscience firm DSM Firmenich told CNBC Wednesday that it is exploring nutritional supplements to complement and compensate for some of the impacts of the weight-loss drugs, with CEO Dimitri de Vreeze describing it as the natural progression for the industry.

“If you go to weight loss and you’re successful, you move to the health, nutrition, lifestyle counter, because you basically want to continue what you have. There we come into play,” de Vreeze told CNBC’s “Squawk Box Europe.”

The weight-loss injections, which rely on a group of drugs called GLP-1 receptor agonists (glucagon-like peptide 1), which work by imitating a naturally occurring gut hormone that helps regulate appetite in the brain.

Studies remain ongoing over some of the further health applications — and potential side effects — of the appetite-suppressing drugs. But de Vreeze said his company was also looking at products to boost muscle retention and protein intake.

“There are some side effects of weight loss drugs and that means it’s more difficult to build up muscle, it’s more difficult to keep your protein level up. And here we come into play. We are using ingredients, developing ingredients where that’s being sort of compensated for,” he said.

Novo Nordisk and Eli Lilly did not immediately respond to CNBC’s request for comment on the comments.

Consumer goods to airlines

DSM is not the only company seeking to capitalize on the growing market for weight loss drugs.

Swiss food giant Nestle announced last month that it’s launching a new frozen food range aimed at GLP-1 drug users. The Vital Pursuits range, which will initially feature 12 items including whole grain bowls and pizzas, is designed as a nutritional “companion” to the drugs, the company said.

CEO Mark Schneider told CNBC last week that while weight loss drugs were shifting consumer behaviors, “nutritional needs don’t go away.”

GLP-1 drugs will “certainly be an interesting addition to all the other needs that we’re trying to meet in the food industry,” Schneider said.

Danone CEO Antoine de Saint-Affrique also told CNBC in April that he sees GLP-1s as “complementary” to the French food company, adding that they would only increase demand for its nutritional products.

Nutritional needs for users of GLP-1 drugs are 'shifting', Nestle CEO says

Whether weight loss meds will leave consumers more or less likely to reach for healthy products is not yet certain, however, according to Barclays analysts.

“Greater adoption of GLP-1 drugs could be thought of as a substitute for categories of food products that are more attuned to health and wellness,” analyst Andrew Lazar said in a research note last year.

“That said, consumers could also eat more weight management foods as they strive to eat healthier and substitute such products over more indulgent snacking alternatives,” he added.

Such shifts could have similar implications for restaurants, food retailers and delivery companies that “proactively pivot” to embrace the drugs, the bank’s analysts added. It cited fast food companies including KFC’s Yum Brands and Shake Shack as potential beneficiaries if consumers view the drugs as “offsetting” such indulgences.

Airlines could also benefit massively from trimmer passengers as they grow increasingly preoccupied by reducing jet-fuel costs. In a September note cited by Bloomberg, Jefferies analyst Sheila Kahyaoglu said United Airlines would save $80 million a year if the average passenger weight fell by 10 pounds.

Even pharmaceutical packaging companies could stand to gain, Barclays said, with companies like Germany’s Gerresheimer seeing a possible 2-4% revenue boost from the estimated $100 billion weight loss drug industry.

Growing weight loss drug competition

It is not yet clear whether such ancillary products can replicate the meteoric rise of weight loss drug companies like Novo Nordisk and Eli Lilly.

“We think it is too early for investors to take definitive positioning outside of healthcare stocks on the impact of GLP-1 drugs, and the range of potential scenarios is very wide,” Barclays analysts wrote.

Weight-loss drugs poised for big 2024 as demand surges

FOLLOW US ON GOOGLE NEWS

Read original article here

Denial of responsibility! Secular Times is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – seculartimes.com. The content will be deleted within 24 hours.

Leave a Comment